Contemporary hormonal contraception and the risk of breast cancer

New England Journal of Medicine

Volumn 377, Issue 23, 2017, Pages 2228-2239

  Mørch, Lina S ^a   Skovlund, Charlotte W ^a   Hannaford, Philip C ^b   Iversen, Lisa ^b   Fielding, Shona ^b   Lidegaard, Øjvind ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER RISK; COHORT ANALYSIS; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; DENMARK; DISEASE ASSOCIATION; DRUG USE; FEMALE; HORMONAL CONTRACEPTION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; ADVERSE DEVICE EFFECT; AGE DISTRIBUTION; BREAST TUMOR; CHEMICALLY INDUCED; INTRAUTERINE CONTRACEPTIVE DEVICE; REGISTER; RISK; RISK ASSESSMENT; TIME FACTOR; YOUNG ADULT;

ESTRADIOL; ESTROGEN; GESTAGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; BREAST NEOPLASMS; CONTRACEPTIVES, ORAL, HORMONAL; DENMARK; ESTRADIOL; ESTROGENS; FEMALE; HUMANS; INTRAUTERINE DEVICES, MEDICATED; PROGESTINS; PROSPECTIVE STUDIES; REGISTRIES; RISK; RISK ASSESSMENT; TIME FACTORS; YOUNG ADULT;

EID: 85038233522     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1700732     Document Type: Article

References (39)

1. World contraceptive patterns 2013. New York: United Nations, Department of Economic and Social Affairs (http://www.un.org/en/development/desa/population/publications/family/contraceptive-wallchart-2013.shtml).
2. Wilson NM, Laursen M, Lidegaard O. Oral contraception in Denmark 1998-2010. Acta Obstet Gynecol Scand 2012; 91: 810-5.
3. Lindh I, Skjeldestad FE, Gemzell-Danielsson K, et al. Contraceptive use in the Nordic countries. Acta Obstet Gynecol Scand 2017; 96: 19-28.
4. Pasqualini JR. Progestins and breast cancer. Gynecol Endocrinol 2007; 23: Suppl 1: 32-41.
5. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet 1996; 347: 1713-27.
6. Pike MC, Ross RK. Progestins and menopause: epidemiological studies of risks of endometrial and breast cancer. Steroids 2000; 65: 659-64.
7. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J Natl Cancer Inst 2000; 92: 328-32.
8. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 2000; 283: 485-91.
9. Colditz GA, Rosner B. Cumulative risk of breast cancer to age 70 years according to risk factor status: data from the Nurses' Health Study. Am J Epidemiol 2000; 152: 950-64.
10. Chlebowski RT, Hendrix SL, Langer RD, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 2003; 289: 3243-53.
11. Chlebowski RT, Kuller LH, Prentice RL, et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med 2009; 360: 573-87.
12. Van Hoften C, Burger H, Peeters PHM, Grobbee DE, Van Noord PAH, Leufkens HG. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer 2000; 87: 591-4.
13. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002; 346: 2025-32.
14. Kumle M, Weiderpass E, Braaten T, Persson I, Adami HO, Lund E. Use of oral contraceptives and breast cancer risk: the Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev 2002; 11: 1375-81.
15. Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control 2003; 14: 151-60.
16. Althuis MD, Brogan DR, Coates RJ, et al. Hormonal content and potency of oral contraceptives and breast cancer risk among young women. Br J Cancer 2003; 88: 50-7.
17. Dumeaux V, Alsaker E, Lund E. Breast cancer and specific types of oral contraceptives: a large Norwegian cohort study. Int J Cancer 2003; 105: 844-50.
18. Dumeaux V, Fournier A, Lund E, Clavel-Chapelon F. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women. Cancer Causes Control 2005; 16: 537-44.
19. Lee SY, Kim MT, Kim SW, Song MS, Yoon SJ. Effect of lifetime lactation on breast cancer risk: a Korean women's cohort study. Int J Cancer 2003; 105: 390-3.
20. Wu MH, Chou YC, Yu JC, et al. Hormonal and body-size factors in relation to breast cancer risk: a prospective study of 11, 889 women in a low-incidence area. Ann Epidemiol 2006; 16: 223-9.
21. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's Oral Contraception Study. BMJ 2007; 335: 651.
22. Shantakumar S, Terry MB, Paykin A, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol 2007; 165: 1187-98.
23. Dorjgochoo T, Shu XO, Li HL, et al. Use of oral contraceptives, intrauterine devices and tubal sterilization and cancer risk in a large prospective study, from 1996 to 2006. Int J Cancer 2009; 124: 2442-9.
24. Rosenberg L, Zhang Y, Coogan PF, Strom BL, Palmer JR. A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009; 169: 473-9.
25. Hunter DJ, Colditz GA, Hankinson SE, et al. Oral contraceptive use and breast cancer: a prospective study of young women. Cancer Epidemiol Biomarkers Prev 2010; 19: 2496-502.
26. Kawai M, Minami Y, Kuriyama S, et al. Reproductive factors, exogenous female hormone use and breast cancer risk in Japanese: the Miyagi Cohort Study. Cancer Causes Control 2010; 21: 135-45.
27. Marchbanks PA, Curtis KM, Mandel MG, et al. Oral contraceptive formulation and risk of breast cancer. Contraception 2012; 85: 342-50.
28. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the Oxford-Family Planning Association contraceptive study. Contraception 2013; 88: 678-83.
29. Beaber EF, Buist DSM, Barlow WE, Malone KE, Reed SD, Li CI. Recent oral contraceptive use by formulation and breast cancer risk among women 20 to 49 years of age. Cancer Res 2014; 74: 4078-89.
30. Jernstrom H, Loman N, Johannsson OT, Borg A, Olsson H. Impact of teenage oral contraceptive use in a populationbased series of early-onset breast cancer cases who have undergone BRCA mutation testing. Eur J Cancer 2005; 41: 2312-20.
31. Kotsopoulos J, Lubinski J, Moller P, et al. Timing of oral contraceptive use and the risk of breast cancer in BRCA1 mutation carriers. Breast Cancer Res Treat 2014; 143: 579-86.
32. Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O. Hormone therapy and ovarian cancer. JAMA 2009; 302: 298-305.
33. Lidegaard O, Lokkegaard E, Jensen A, Wessel Skovlund C, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012; 366: 2257-66.
34. Nielsen LH, Lokkegaard E, Andreasen AH, Keiding N. Using prescription registries to define continuous drug use: how to fill gaps between prescriptions. Pharmacoepidemiol Drug Saf 2008; 17: 384-8.
35. Soini T, Hurskainen R, Grenman S, Maenpaa J, Paavonen J, Pukkala E. Cancer risk in women using the levonorgestrelreleasing intrauterine system in Finland. Obstet Gynecol 2014; 124: 292-9.
36. Lockhat FB, Emembolu JE, Konje JC. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel. Fertil Steril 2005; 83: 398-404.
37. Raudaskoski T, Tapanainen J, Tomas E, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. BJOG 2002; 109: 136-44
38. Haimov-Kochman R, Amsalem H, Adoni A, Lavy Y, Spitz IM. Management of a perforated levonorgestrel-medicated intrauterine device - a pharmacokinetic study: case report. Hum Reprod 2003; 18: 1231-3.
39. Iversen L, Sivasubramaniam S, Lee AJ, Fielding S, Hannaford PC. Lifetime cancer risk and combined oral contraceptives: the Royal College of General Practitioners' Oral Contraception Study. Am J Obstet Gynecol 2017; 216(6): 580.e1-580.e9.